Original From: Genomeweb
Cue Health said on Wednesday that it has received interim order authorization from Health Canada to sell its at-home molecular COVID-19 self-test in that country.
The isothermal nucleic acid amplification test consists of the single-use test cartridge and a wand for collecting lower nasal swab samples. It runs on the portable Cue Health Monitoring System, which was also authorized for sale in Canada, and displays test results on a connected mobile device in about 20 minutes via an app.
The test received Emergency Use Authorization from the US Food and Drug Administration in mid-2020 and CE marking in early 2021.
Cue Health said that it will begin offering the test in Canada for both professional and at-home consumer use without a prescription.
"Following the successful launch of our smart home lab platform in the US, we are pleased to now offer Canadian consumers access to our molecular COVID-19 self-test that combines accuracy, speed, and reliability," Cue Health Cofounder and CEO Ayub Khattak said in a statement.
Last month, the San Diego-based company inked a distribution deal for its COVID-19 test with Cardinal Health. It also just launched a subscription service for COVID-19 testing and virtual care.
Source: Cue Health Gets Authorization to Offer At-Home COVID-19 Test in Canada
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.